Continued progress in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) toward first subject treated, on track to take place in ...
FDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably ...
Call Scheduled for March 31, 2025, at 8:30 AM Eastern Time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback